Profile data is unavailable for this security.
About the company
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
- Revenue in MXN (TTM)17.47bn
- Net income in MXN1.60bn
- Incorporated1996
- Employees1.63k
- LocationGenomma Lab Internacional SAB de CVEdificio SamaraAntonio Dovali Jaime no. 70 Piso 2Colonia Santa FeALVARO OBREGON 01210MexicoMEX
- Phone+52 5 550810000
- Fax+52 5 550810000
- Websitehttps://www.genommalab.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Luye Pharma Group Ltd | 17.80bn | 2.17bn | 25.86bn | 5.23k | 11.91 | 0.7047 | 5.92 | 1.45 | 0.22 | 0.22 | 1.80 | 3.72 | 0.236 | 2.44 | 3.02 | 1,286,903.00 | 3.11 | 2.80 | 5.47 | 4.45 | 68.73 | 70.53 | 13.18 | 10.39 | 1.20 | 3.14 | 0.4103 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| Guangxi Wuzhou Zhongheng Group Co Ltd | 8.06bn | -70.36m | 25.91bn | 2.89k | -- | 1.41 | -- | 3.21 | -0.0074 | -0.0074 | 0.8379 | 1.89 | 0.2476 | 2.17 | 4.52 | 990,180.10 | -0.3138 | 2.26 | -0.4836 | 3.38 | 42.33 | 72.05 | -1.27 | 7.27 | 2.39 | -- | 0.1767 | 45.67 | 14.10 | -1.26 | 6.69 | -32.76 | -4.56 | -30.12 |
| Shenzhen Chipscreen Biosciences Co Ltd | 1.85bn | -198.44m | 26.66bn | 1.06k | -- | 5.75 | -- | 14.40 | -0.1709 | -0.1709 | 1.60 | 4.03 | 0.2022 | 2.34 | 4.47 | 620,847.90 | -2.17 | 1.32 | -2.44 | 1.54 | 86.24 | 93.29 | -10.72 | 6.97 | 2.76 | -0.5584 | 0.441 | 0.00 | -1.18 | 28.81 | 408.09 | 23.31 | 10.23 | -- |
| Genomma Lab Internacional SAB de CV | 17.47bn | 1.60bn | 26.67bn | 1.63k | 15.43 | 2.22 | 14.20 | 1.53 | 1.69 | 1.69 | 18.48 | 11.80 | 0.7663 | 2.81 | 3.85 | 10,695,950.00 | 7.03 | 5.79 | 10.00 | 8.64 | 63.56 | 61.70 | 9.18 | 7.88 | 1.56 | 3.96 | 0.3738 | 16.85 | -2.10 | 6.90 | -21.90 | -0.4465 | -26.37 | -- |
| Sanofi Consumer Healthcare India Ltd | -24.17bn | -24.17bn | 26.71bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| KAKEN PHARMACEUTICAL CO., LTD. | 11.53bn | 2.41bn | 26.94bn | 1.14k | 9.21 | 1.09 | 9.76 | 2.34 | 481.71 | 481.71 | 2,303.80 | 4,076.80 | 0.4864 | 1.98 | 3.88 | 76,867,840.00 | 10.17 | 6.83 | 11.66 | 7.87 | 60.66 | 54.78 | 20.91 | 14.48 | 4.47 | -- | 0.0243 | 51.25 | -1.29 | -5.21 | 47.52 | -14.70 | 0.3639 | 0.00 |
| Ocular Therapeutix Inc | 1.25bn | -3.56bn | 27.13bn | 267.00 | -- | 3.79 | -- | 21.62 | -1.30 | -1.30 | 0.4442 | 2.25 | 0.1883 | 2.48 | 2.28 | 230,116.10 | -53.42 | -46.70 | -59.98 | -54.18 | 90.59 | 89.36 | -283.75 | -228.65 | 12.94 | -27.52 | 0.1615 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| North China Pharmaceutical Co Ltd | 27.39bn | 223.98m | 27.16bn | 10.16k | 120.57 | 1.79 | -- | 0.9917 | 0.0465 | 0.0465 | 5.68 | 3.13 | 0.4492 | 2.67 | 4.34 | 955,385.00 | 0.6731 | -0.2978 | 1.54 | -0.7042 | 29.79 | 35.73 | 1.50 | -0.5985 | 0.5609 | 1.64 | 0.6482 | -- | -3.62 | 1.89 | 100.71 | -49.62 | 4.22 | -19.73 |
| GuangYuYuan Chinese Herbal Medicn Co Ltd | 3.50bn | 385.31m | 27.20bn | 1.81k | 70.58 | 6.15 | -- | 7.77 | 0.279 | 0.279 | 2.53 | 3.20 | 0.5011 | 0.5647 | 2.60 | 684,557.40 | 6.04 | -2.10 | 8.71 | -3.16 | 72.21 | 69.74 | 12.05 | -6.00 | 0.9873 | 21.00 | 0.0267 | -- | 13.56 | -4.53 | 136.03 | -24.78 | -58.35 | -- |
| Harbin Pharmaceutical Group Co., Ltd. | 45.76bn | 1.73bn | 27.43bn | 9.85k | 15.96 | 1.87 | -- | 0.5994 | 0.2418 | 0.2418 | 6.38 | 2.07 | 1.15 | 6.29 | 3.47 | 1,646,115.00 | 4.78 | 0.7414 | 12.56 | 1.89 | 27.60 | 23.87 | 4.15 | 0.7294 | 1.11 | 36.80 | 0.3633 | 0.00 | 11.93 | 7.41 | -14.88 | 2.69 | -5.38 | -- |
| Indivior PLC | 23.43bn | -2.88bn | 27.43bn | 1.05k | -- | -- | -- | 1.17 | -0.864 | -0.864 | 6.43 | -0.7175 | 0.7024 | 1.29 | 4.70 | 867,103.60 | -8.63 | 1.32 | -22.00 | 2.62 | 83.00 | 83.69 | -12.29 | 2.68 | 0.6848 | -- | 1.76 | 0.00 | 21.31 | 1.69 | 96.00 | -- | 5.27 | -- |
Data as of Nov 22 2024. Currency figures normalised to Genomma Lab Internacional SAB de CV's reporting currency: Mexican New Peso MXN
20.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 45.14m | 4.43% |
| Skagen AS (Investment Management)as of 30 Sep 2024 | 30.46m | 2.99% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 28.17m | 2.76% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 19.68m | 1.93% |
| BlackRock M�xico SA de CV Asesor en Inversiones Independienteas of 07 Nov 2024 | 17.78m | 1.74% |
| Lemanik Asset Management SAas of 30 Jun 2024 | 17.62m | 1.73% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 17.00m | 1.67% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 13.62m | 1.34% |
| Invesco Asset Management Ltd.as of 30 Sep 2024 | 13.49m | 1.32% |
| BlackRock M�xico Operadora SA de CV SOFIas of 30 Aug 2024 | 10.43m | 1.02% |
More ▼
Data from 30 Aug 2024 - 13 Nov 2024Source: FactSet Research Systems Inc.
